Taylor Wealth Management Partners bought a new stake in shares of Vyant Bio, Inc. (NASDAQ:VYNT) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 85,621 shares of the company’s stock, valued at approximately $320,000.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in VYNT. Blankinship & Foster LLC acquired a new position in shares of Vyant Bio in the second quarter worth about $767,000. Renaissance Technologies LLC purchased a new stake in Vyant Bio in the 1st quarter worth $839,000. BlackRock Inc. acquired a new stake in shares of Vyant Bio in the first quarter valued at about $764,000. Geode Capital Management LLC purchased a new stake in shares of Vyant Bio during the first quarter worth about $270,000. Finally, Virtu Financial LLC purchased a new position in Vyant Bio in the 1st quarter valued at about $182,000. 7.83% of the stock is currently owned by hedge funds and other institutional investors.
In other news, CEO John A. Roberts acquired 10,406 shares of the company’s stock in a transaction that occurred on Monday, August 23rd. The stock was purchased at an average price of $2.41 per share, with a total value of $25,078.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Paul R. Hansen acquired 20,000 shares of the stock in a transaction that occurred on Thursday, August 19th. The stock was acquired at an average price of $2.35 per share, with a total value of $47,000.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 41,406 shares of company stock worth $102,218. 15.00% of the stock is currently owned by corporate insiders.
About Vyant Bio
Vyant Bio, Inc is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline. The company with capabilities in data, science (both biology and chemistry), engineering, and regulatory, it rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities.
Recommended Story: What is a Market Correction?
Want to see what other hedge funds are holding VYNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vyant Bio, Inc. (NASDAQ:VYNT).
Receive News & Ratings for Vyant Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyant Bio and related companies with MarketBeat.com's FREE daily email newsletter.